ULCERATIVE-NECROTIZING ANGIITIS ON A BACKGROUND OF RECEPTION OF LENVATINIB IN THYROID CANCER
Ekaterina V. Orlova , O. V Grabovskaya , L. M Smirnova , L. A Shestakova , N. I Melikova , L. N Kayumova
Russian Journal of Skin and Venereal Diseases ›› 2019, Vol. 22 ›› Issue (1-2) : 29 -32.
ULCERATIVE-NECROTIZING ANGIITIS ON A BACKGROUND OF RECEPTION OF LENVATINIB IN THYROID CANCER
The information about modern targeted drugs used in chemotherapy regimens for different types of cancer is presented. The mechanisms of pathogenesis of the development of undesirable skin reactions in the presence of tyrosine kinase receptor inhibitors are described. The clinical case of a rarely occurring reaction to drugs inhibitors of vascular growth factor in the form of ulcerative-necrotic skin lesions in a 63-year-old patient is presented.
thyroid cancer / tyrosine kinase inhibitor / ulcerative-necrotizing vasculitis / sorafenib lenvatinib / skin toxicity
| [1] |
Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 2006; 91(8): 2892-9. |
| [2] |
Sgouros G., Kolbert K.S., Sheikh A., Pentlow K.S., Mun E.F., Barth A., et al. Patient-specific dosimetry for I131 thyroid cancer therapy using I124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J. Nucl. Med. 2004; 45(8): 1366-72. |
| [3] |
Каприн А.Д., Старинский В.В., Петров Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИЦ радиологии Минздрава России; 2018. http://www.oncology.ru/service/statistics; https://www.rakfond.org/2018/10/19/cancer-statistics-incidence-and-mortality_ru/ |
| [4] |
Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998; 83(12): 2638-48. |
| [5] |
Sciuto R., Romano L., Rea S., Marandino F., Sperduti I., Maini C.L. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann. Oncol. 2009; 20(10): 1728-35. |
| [6] |
Pacini F., Castagna M.G. Approach to and treatment of differentiated thyroid carcinoma. Med. Clin. North Am. 2012; 96(2): 369-83. |
| [7] |
Xing M., Haugen B., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013; 381(9871): 1058-69. |
| [8] |
Amin A., Badwey A., El-Fatah S. Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin. Nucl. Med. 2014; 39(2): 142-6. |
| [9] |
Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483): 1357-60. |
| [10] |
Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol. Cell Endocrinol. 2010; 321(1): 20-8. |
| [11] |
Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003; 284(1): 99-110. |
| [12] |
Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008; 14(17): 5459-65. |
| [13] |
Grande E., Diez J.J., Zafon C., Capdevila J. Thyroid cancer: molecular aspects and new therapeutic strategies. J. Thyroid. Res. 2012; 2012: 847108. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
